New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
Mamilli last held the role of Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health at Zoetis
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
For people with relapsed or refractory diffuse large B-cell lymphoma
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Subscribe To Our Newsletter & Stay Updated
